Nephros Inc Revenue Growth Rates (NEPH), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Nephros Inc   (NASDAQ: NEPH)
 

NEPH's Revenue Growth by Quarter and Year

Nephros Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NEPH Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 6.02
1st Quarter March 4.99
FY 11.01

NEPHs Annual Revenue
Nephros Inc 's Revenue in the fiscal year 2025 $ 18.63 millions
Nephros Inc 's Revenue in the fiscal year 2024 $ 13.72 millions
Nephros Inc 's Revenue in the fiscal year 2023 $ 13.41 millions
Nephros Inc 's Revenue in the fiscal year 2022 $ 9.98 millions
Nephros Inc 's Revenue in the fiscal year 2021 $ 10.40 millions




NEPH Revenue second quarter 2026 Y/Y Growth Comment
Nephros Inc achieved in the second quarter 2026, above Company average Revenue rise of 58.34% year on year, to $ 6.02 millions.

Looking into second quarter 2026 results within Medical Equipment & Supplies industry 23 other companies have achieved higher Revenue growth. While Nephros Inc ' s Revenue jump of 58.34% ranks overall at the positon no. 408 in the second quarter 2026.


NEPH Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 50.89 % 30.23 % 34.37 %
3rd Quarter September - 24.44 % -1.25 % 32.37 %
2nd Quarter June 58.34 % 30.58 % -5.52 % 6.94 %
1st Quarter March 20.24 % 30.09 % -13.78 % 71.3 %
FY   - 35.69 % 2.39 % -

Financial Statements
Nephros Inc 's second quarter 2026 Revenue $ 6.02 millions NEPH's Income Statement
Nephros Inc 's second quarter 2025 Revenue $ 3.80 millions Quarterly NEPH's Income Statement


NEPH Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 72.45 % 42.22 % 7.84 %
3rd Quarter September - 3.16 % 8.25 % 3.57 %
2nd Quarter June 20.58 % -8.43 % -8.78 % -16.76 %
1st Quarter March -26.18 % -7.37 % -7.27 % 44.53 %
FY (Year on Year)   - 35.69 % 2.39 % -


Back to NEPH Growth rate Comparisons >> Back to NEPH Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #24
Healthcare Sector #106
Overall #408

Revenue Y/Y Growth Statistics
High Average Low
96.09 % 22.14 % -52.59 %
(Jun 30 2015)   (Mar 31 2021)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #24
Healthcare Sector #106
Overall #408
Revenue Y/Y Growth Statistics
High Average Low
96.09 % 22.14 % -52.59 %
(Jun 30 2015)   (Mar 31 2021)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Nephros Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
100 % 7.06 % -43.56 %
(Sep 30 2012)  


NEPH's II. Quarter Q/Q Revenue Comment
Nephros Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 20.58%, to $ 6.02 millions, from $4.99 millions in the first quarter.
NEPH is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Medical Equipment & Supplies industry 22 other companies have achieved higher Revenue quarter on quarter growth. While Nephros Inc 's Revenue growth quarter on quarter, overall rank is 493.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #23
Healthcare Sector #97
Overall #493
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #23
Healthcare Sector #97
Overall #493
Revenue Q/Q Growth Statistics
High Average Low
100 % 7.06 % -43.56 %
(Sep 30 2012)  


NEPH's II. Quarter Q/Q Revenue Comment
Nephros Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 20.58%, to $ 6.02 millions, from $4.99 millions in the first quarter.
NEPH is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Medical Equipment & Supplies industry 22 other companies have achieved higher Revenue quarter on quarter growth. While Nephros Inc 's Revenue growth quarter on quarter, overall rank is 493.


Nephros Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 21.69 $ 19.46 $ 18.63 $ 16.34 $ 15.57
Y / Y Revenue Growth (TTM) 39.25 % 32.5 % 35.72 % 28.83 % 22.35 %
Year on Year Revenue Growth Overall Ranking # 747 # 1075 # 1767 # 1058 # 594
Seqeuential Revenue Change (TTM) 11.42 % 4.5 % 13.99 % 4.92 % 6.01 %
Seq. Revenue Growth (TTM) Overall Ranking # 1910 # 1695 # 1200 # 1484 # 1631


Cumulative Revenue growth Comment
Nephros Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 39.25% year on year, to $ 22 millions if the fiscal year would have ended in Jun 30 2026.
Nephros Inc 's trailing twelve months Revenue growth was higher than company's average 38.21% and higher than 32.5% growth in Mar 31 2026.
But from twelve months ended Mar 31 2026 rise was beneth at 11.42 % from $19.46 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at38.21%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 11.42 % increase from $19.46 millions in the period from Mar 31 2026 to Jun 30 2025.

In the Healthcare sector 155 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 747, from total ranking in previous quarter at 1075.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 108
Healthcare Sector # 156
Overall # 747

Revenue TTM Y/Y Growth Statistics
High Average Low
251.72 %
 38.21 %
-20.97 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 108
Sector # 297
S&P 500 # 1910
Cumulative Revenue growth Comment
Nephros Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 39.25% year on year, to $ 22 millions if the fiscal year would have ended in Jun 30 2026.
Nephros Inc 's trailing twelve months Revenue growth was higher than company's average 38.21% and higher than 32.5% growth in Mar 31 2026.
But from twelve months ended Mar 31 2026 rise was beneth at 11.42 % from $19.46 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at38.21%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 11.42 % increase from $19.46 millions in the period from Mar 31 2026 to Jun 30 2025.

In the Healthcare sector 155 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 747, from total ranking in previous quarter at 1075.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 108
Healthcare Sector # 156
Overall # 747

Revenue TTM Y/Y Growth Statistics
High Average Low
251.72 %
38.21 %
-20.97 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 108
Sector # 297
S&P 500 # 1910




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NEPH's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Ptc Therapeutics inc 101.55%$ 101.548 millions
Eton Pharmaceuticals Inc 98.63%$ 98.631 millions
Immunitybio inc 93.91%$ 93.907 millions
Syndax Pharmaceuticals Inc 91.76%$ 91.759 millions
Phathom Pharmaceuticals Inc 88.02%$ 88.021 millions
Fennec Pharmaceuticals Inc 85.18%$ 85.184 millions
Alamar Biosciences Inc 82.08%$ 82.075 millions
Seastar Medical Holding Corp81.95%$ 81.953 millions
Sera Prognostics Inc 76.47%$ 76.471 millions
Innovative Eyewear Inc 74.46%$ 74.459 millions
Madrigal Pharmaceuticals Inc 71.17%$ 71.169 millions
Tg Therapeutics Inc 70.27%$ 70.272 millions
Tarsus Pharmaceuticals Inc 69.41%$ 69.406 millions
Hyperfine Inc 67.70%$ 67.698 millions
Alnylam Pharmaceuticals Inc 66.86%$ 66.856 millions
Emergent Biosolutions Inc 66.29%$ 66.288 millions
Vivos Therapeutics Inc 65.69%$ 65.691 millions
Iovance Biotherapeutics inc 65.65%$ 65.654 millions
Billiontoone Inc 64.40%$ 64.403 millions
Anteris Technologies Global Corp 63.27%$ 63.269 millions
Nexgel Inc 63.24%$ 63.242 millions
Carlsmed Inc 59.58%$ 59.575 millions
Sonoma Pharmaceuticals Inc 59.55%$ 59.552 millions
Arcutis Biotherapeutics Inc 59.33%$ 59.331 millions
Nephros Inc 58.55%$ 58.551 millions
Bioadaptives Inc 54.95%$ 54.955 millions
Zevra Therapeutics Inc 53.25%$ 53.251 millions
Beyond Air Inc 52.94%$ 52.941 millions
Caredx Inc 52.23%$ 52.226 millions
Bioxcel Therapeutics Inc 51.67%$ 51.667 millions


About Nephros Inc Revenue Growth Rates (NEPH), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Nephros Inc (CIK 1196298).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001493152-26-036851
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Nephros Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.